Implied from what? "In patients whose tumours are difficult to...

Implied from what?

"In patients whose tumours are difficult to measure, clinical response is being determined on the basis of PSA levels and pain scores.

Cohort 1 (400 mg Veyonda: 3 patients (Patients # 1-3) were assessed at 12 weeks as having stable disease by scan (RECIST assessment). At 24 weeks, Patients #1 and 3 remain stable on the basis of scans, while Patient # 2 has progressed.

Cohort 2 (800 mg): 1 patient (#7) was assessed at 12 weeks as having a partial response. At 24 weeks this patient continues to have a partial response including a strong decreasing PSA response. Cohort 3 (1,200 mg): Patient #9 at 12 weeks continues to have a partial response and a strong decreasing PSA response.